Despite major Election Day victories in eight out of nine states in November, the U.S. marijuana movement may now be derailed.
It seems the worst-case scenario could be unfolding for marijuana investors and supporters. White House spokesperson Sean Spicer told reporters Thursday that President Trump and Attorney General Jeff Sessions intend to spearhead “greater enforcement” of the federal marijuana ban.
“There are two distinct issues here: medical marijuana and recreational marijuana,” Spicer said. “There’s still a federal law that we need to abide by when it comes to recreational marijuana and other drugs of that nature.”
While Spicer seemed to be drawing a distinction between recreational and medical marijuana use, Height Securities points out that the law draws no such distinction.
“Under current federal law, however, there is no distinction between intended use in how the drug is classified/should be viewed by federal law enforcement,” the firm wrote in a research note.
In other words, by the letter of the law, a federal marijuana crackdown should impact both the medical and recreational marijuana markets equally.
“While shutting down ‘recreational’ cannabis would be a tremendous blow to the industry, Spicer made it very clear that ‘medical’ cannabis is sacrosanct,” Alan Brochstein, founding partner at New Cannabis Ventures and founder of 420 Investor, told Benzinga. “I would argue that a medical-only industry will still be a large and growing industry.”
GW Pharmaceuticals PLC-ADR GWPH 1.16% spokesperson Stephen Shultz tells Benzinga its cannabinoid drug candidates should not be impacted by any potential crackdown in federal enforcement.
“Once a Schedule 1 drug that is based on cannabinoids is approved by the FDA, then there’s an automatic process for rescheduling of that approved medicine, not for marijuana or cannabis in general, but just for the compound that was approved by the FDA,” Shultz explained.
Schultz said if the company’s Epidiolex drug is approved by the FDA, investors can expect cannabidiol to be rescheduled and federally legalized shortly thereafter.
In that respect, shareholders of GW Pharmaceuticals, Zynerba Pharmaceuticals Inc ZYNE 0.14% and other marijuana-based biotech stocks shouldn’t be…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
